Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. Liz Cooney here filling in for Theresa. Our colleague, Europe correspondent Andrew Joseph, has been covering the European Society of Cardiology meeting in Munich this past weekend (more below). I typically pick up American Heart Association meetings stateside.
Which group has the better venues, assuming one ever escapes the giant conference halls long enough to find out? ESC was in Madrid last year and will land in Milan in 2027. AHA has recently toggled between Chicago and New Orleans, but Boston (STAT’s HQ, btw) gets the nod next year. Tell me your preferences as a conference-goer, or a global traveler.
Maybe ‘mRNA’ is no longer a four-letter word
Maybe, just maybe, using mRNA technology to beat back cancer will mean “mRNA” and “vaccine” are no longer taboo. That hope comes after Moderna and Merck’s stunning success with an mRNA vaccine that lowered the odds of surgically removed melanoma spreading or coming back. Reports on top-line results released last week for the neoantigen cancer immunotherapy seemed to dance around calling it an mRNA vaccine.
